Telo Genomics Launches Retrospective Blood-Based MRD Study with University of Athens as Part of 2026 Multi-Center Validation Program

Core Viewpoint - Telo Genomics Corp. has initiated a new clinical trial for Minimal Residual Disease (MRD) in multiple myeloma, collaborating with the University of Athens to enhance its MRD validation program and assess the clinical utility of its TeloView®MRD technology [1][2]. Company Overview - Telo Genomics is a biotech company specializing in advanced telomere analytics, focusing on diagnostic and prognostic innovations, particularly in oncology and neurological diseases [8]. - The company aims to provide actionable insights through its proprietary technology, which has been validated in over 160 peer-reviewed publications and 30 clinical studies involving more than 3,000 patients [8]. Clinical Trial Details - The new clinical trial is part of Telo's multi-center MRD validation program, utilizing well-characterized clinical blood samples from the University of Athens, with an average follow-up of approximately three years [2]. - The study will evaluate the prognostic performance of TeloView®MRD in predicting relapse risk compared to Next-Generation Flow (NGF), a widely used MRD assessment method [3]. Technology and Performance - TeloView®MRD is designed to detect disease with high sensitivity, achieving a limit of detection of 1 in 10^7, significantly outperforming NGF, which can reach a sensitivity of 1 in 10^6 [4]. - In addition to MRD enumeration, TeloView®MRD analyzes the 3D genomic architecture of individual MRD cells, potentially offering additional prognostic insights [4]. Market Context - The global MRD testing market is projected to reach USD 4.1 billion by 2032, driven by advancements in drug development and a growing emphasis on personalized healthcare [6]. - Multiple myeloma is a significant health challenge, with 35,000 new cases annually in the US and a total addressable market for MM assays exceeding 750,000 tests per year [7]. Future Developments - Telo Genomics is advancing its prospective MRD trials with Cleveland Clinic and Jewish General Hospital and plans to announce additional retrospective studies in Q1 2026 [5].